Central Retinal Vein Occlusion Following BNT162b2 (Pfizer-BioNTech) COVID-19 Messenger RNA Vaccine

U.S, 1 December 2021, Shah et al, Retinal Cases & Brief Reports

Summary

A 27-year-old female was diagnosed with central retinal vein occlusion (CRVO) a few days after her first dose of the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine. Detailed elicitation of her history and a full hypercoagulable workup did not reveal any primary risk factors that could have explained her disease process. After the patient received the second dose, her symptoms deteriorated significantly and worsening peripapillary hemorrhage were seen on DFE. The patient was treated with intravitreal injections of ranibizumab and followed closely, which showed improvement of her CRVO.

Conclusion:
Given the chronology of the patient’s condition, we believe that the CRVO which occurred due to the first dose was exacerbated by an intense immunological reaction after the second dose.

Download PDF

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s